News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Andrea Sitlinger, MD, Duke University Cancer Institute

Articles by Andrea Sitlinger, MD, Duke University Cancer Institute

Advice for Community Oncologists on Treating HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Treatments for Relapsed/Refractory HCL in Pipeline

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

The Role of CD22-targeted Immunotoxins in HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Landscape Change in the Treatment of Relapsed/Refractory HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Historical Treatment for Relapsed/Refractory HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Combination First-line Therapy in Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Determining When to Treat and First-Line Therapy for HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Differential Diagnosis and Molecular Tests in Identifying HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Signs and Tests for Diagnosis and Prognosis of HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Molecular Genetic Changes for Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Introduction and Epidemiology of Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Latest Updated Articles

Differential Diagnosis and Molecular Tests in Identifying HCL
Published: June 30th 2020 | Updated:
Advice for Community Oncologists on Treating HCL
Published: June 30th 2020 | Updated:
$Landscape Change in the Treatment of Relapsed/Refractory HCL$
Landscape Change in the Treatment of Relapsed/Refractory HCL
Published: June 30th 2020 | Updated:
Molecular Genetic Changes for Hairy Cell Leukemia
Published: June 30th 2020 | Updated:
Signs and Tests for Diagnosis and Prognosis of HCL
Published: June 30th 2020 | Updated:
When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL
Published: June 30th 2020 | Updated:

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma

Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL